AmCad BioMed Corporation (TPEX:4188)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.00
0.00 (0.00%)
Apr 29, 2026, 1:22 PM CST
-10.45%
Market Cap 759.99M
Revenue (ttm) 30.44M
Net Income (ttm) -55.72M
Shares Out 63.33M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,091
Average Volume 32,774
Open 12.00
Previous Close 12.00
Day's Range 12.00 - 12.10
52-Week Range 11.80 - 19.55
Beta 0.40
RSI 36.70
Earnings Date May 8, 2026

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2008
Employees 34
Stock Exchange Taipei Exchange
Ticker Symbol 4188
Full Company Profile

Financial Performance

In 2025, AmCad BioMed's revenue was 30.44 million, a decrease of -42.69% compared to the previous year's 53.11 million. Losses were -55.72 million, 10.2% more than in 2024.

Financial Statements

News

There is no news available yet.